
The senolytic drug pipeline is narrowing toward a smaller set of credible candidates
DDDr. Dereck Mush, MD, MBA
Apr 14Micro-robotic devices for targeted therapeutic delivery inside the central nervous system.
The company develops miniature, magnetically controlled micro-robots designed to navigate the brain and spinal cord. These devices deliver therapeutics directly to deep-seated tumors and neurological targets, serving neurosurgeons and biopharmaceutical researchers seeking localized treatment options.
Notable investors: Khosla Ventures, Upfront Ventures, Deep Insight, Revolution.

The HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules

